At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMNN Imunon, Inc.
Post-Mkt 03-23 16:46:06 EDT
2.98
+0.11
+3.83%
盘后2.98
+0.000.00%
16:10 EDT
High3.03Low2.87Vol32.96K
Open2.89D1 Closing2.87Amplitude5.49%
Mkt Cap10.13MTradable Cap10.03MTotal Shares3.40M
T/O96.82KT/O Rate0.98%Tradable Shares3.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Imunon files prospectus supplement for USD 7 million at-the-market common stock offering
Reuters  ·  30 minutes ago
Imunon files prospectus supplement for USD 7 million at-the-market common stock offering
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-23 18:00
Calendar of U.S. Earnings Expected in the Week Ahead
Imunon Inc expected to post a loss of $1.17 a share - Earnings Preview
Reuters  ·  03-20
Imunon Inc expected to post a loss of $1.17 a share - Earnings Preview
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-20
Calendar of U.S. Earnings Expected in the Week Ahead
Imunon Inc expected to post a loss of $1.17 a share - Earnings Preview
Reuters  ·  02-23
Imunon Inc expected to post a loss of $1.17 a share - Earnings Preview
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN)
TIPRANKS  ·  02-06
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN)
BUZZ-U.S. STOCKS ON THE MOVE-OneSpaWorld, IMUNON, Cigna
Reuters  ·  02-05
BUZZ-U.S. STOCKS ON THE MOVE-OneSpaWorld, IMUNON, Cigna
BUZZ-IMUNON rises on plan to shift resources to ovarian cancer therapy
Reuters  ·  02-05
BUZZ-IMUNON rises on plan to shift resources to ovarian cancer therapy
BRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study
Reuters  ·  02-05
BRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study
Imunon announces reorganization to eliminate headcount for Phase 3 trial
TIPRANKS  ·  02-05
Imunon announces reorganization to eliminate headcount for Phase 3 trial
Imunon Inc. Grants Retiring Chief Scientific Officer Severance and Consulting Retainer
Reuters  ·  02-05
Imunon Inc. Grants Retiring Chief Scientific Officer Severance and Consulting Retainer
Imunon-Entwicklungschef Khursheed Anwer tritt zurück
Reuters  ·  02-05
Imunon-Entwicklungschef Khursheed Anwer tritt zurück
Imunon Inc - Khursheed Anwer to Retire as Evp and Cso
THOMSON REUTERS  ·  02-05
Imunon Inc - Khursheed Anwer to Retire as Evp and Cso
Imunon Inc: Phase 3 Study Enrollment Remains Ahead of Schedule and Advances Company Toward Future Bla Filing
THOMSON REUTERS  ·  02-05
Imunon Inc: Phase 3 Study Enrollment Remains Ahead of Schedule and Advances Company Toward Future Bla Filing
Imunon Inc: Announces Strategic Reorganization That Will Eliminate Headcount Not Essential to Phase 3 Trial
THOMSON REUTERS  ·  02-05
Imunon Inc: Announces Strategic Reorganization That Will Eliminate Headcount Not Essential to Phase 3 Trial
Imunon Inc - Strategic Restructuring to Cut Non-Essential Expenses
THOMSON REUTERS  ·  02-05
Imunon Inc - Strategic Restructuring to Cut Non-Essential Expenses
Imunon Inc. Files Initial Beneficial Ownership Statement for CFO Jeffrey Wayne Church
Reuters  ·  01-21
Imunon Inc. Files Initial Beneficial Ownership Statement for CFO Jeffrey Wayne Church
BRIEF-Imunon Inc - Interim CFO Kimberly Graper To Resign January 14, 2026 - SEC Filing
Reuters  ·  01-08
BRIEF-Imunon Inc - Interim CFO Kimberly Graper To Resign January 14, 2026 - SEC Filing
Imunon Inc. Sets $30,000 Monthly Retainer for Interim CFO Church
Reuters  ·  01-08
Imunon Inc. Sets $30,000 Monthly Retainer for Interim CFO Church
Imunon to Raise Roughly $7 Million From Registered Direct Offering
MT Newswires Live  ·  2025-12-30
Imunon to Raise Roughly $7 Million From Registered Direct Offering

Introduction

Company Name.
Imunon, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Issue price:
--